Physician profile
Farooque Ahmed
NPI 1164424982
$4,734.67
in general payments reported to CMS, 2019-2025
33 companies · $917 in 2025
The $917 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $304 · 2021: $961 · 2022: $745 · 2023: $684 · 2024: $914 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.70 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $828.52 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $484.60 | 2020-2025 | Farxiga, Airsupra, Lokelma |
| Janssen Pharmaceuticals, INC | $379.39 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $319.90 | 2019-2025 | |
| Lilly USA, LLC | $233.29 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $224.66 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $218.70 | 2020-2025 | |
| Corcept Therapeutics | $206.19 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.54 | 2020-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $157.59 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.52 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $150.53 | 2021-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $144.02 | 2020-2023 | Gattex |
| Mayne Pharma Commercial LLC | $122.21 | 2021 | |
| Inspire Medical Systems, INC. | $103.85 | 2023 | Inspire |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $102.11 | 2021-2024 | |
| Novo Nordisk INC | $101.23 | 2020-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.37 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $81.66 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $79.76 | 2021-2023 | Dificid |
| Genzyme Corporation | $78.70 | 2024 | |
| Esperion Therapeutics, INC. | $45.52 | 2021-2022 | |
| Radius Health, INC. | $33.75 | 2025 | Tymlos |
| Dexcom, INC. | $33.22 | 2021-2024 | Dexcom G6 Transmitter |
| Tactile Systems Technology INC | $27.16 | 2019 | |
| Amarin Pharma, INC. | $24.25 | 2021 | |
| Shire North American Group INC | $23.14 | 2019 | |
| Boston Scientific Corporation | $22.21 | 2023 | Watchman Access System |
| Antares Pharma, INC. | $22.02 | 2025 | Xyosted |
| Smith+Nephew, INC. | $16.74 | 2021 | |
| Redhill Biopharma INC. | $16.60 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.48 | 2022 | |
| Melinta Therapeutics, LLC | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farooque Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.